Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Sep;51(9):1649-1657.
doi: 10.1007/s11255-019-02243-w. Epub 2019 Aug 1.

Effect of febuxostat on oxidative stress in hemodialysis patients with endothelial dysfunction: a randomized, placebo-controlled, double-blinded study

Mona Alshahawey  1 , Sara M Shaheen  2 , Tamer Elsaid  3 , Nagwa Ali Sabri  1
Affiliations
Randomized Controlled Trial

Effect of febuxostat on oxidative stress in hemodialysis patients with endothelial dysfunction: a randomized, placebo-controlled, double-blinded study

Mona Alshahawey et al. Int Urol Nephrol. 2019 Sep.

Abstract

Purpose: Oxidative stress, which is most likely a key mediator in the development of cardiovascular disease, is implicated in the progression and deterioration of chronic kidney disease. Patients on hemodialysis exhibit the excessive generation of oxidative stressors, which may also be responsible for the endothelial dysfunction prevalent in these patients. Febuxostat, an inhibitor of xanthine oxidase enzyme, is emerging as a novel drug in the amelioration of oxidative stress status. However, studies regarding its effect among hemodialysis patients are still lacking.

Methods: This prospective, block-randomized, double-blinded, placebo-controlled study was carried out to assess the effect of oral 40 mg febuxostat on oxidative stress in hemodialysis patients. In total, fifty-seven eligible patients were randomly assigned to either a drug group or a placebo group for the 2-month study period. Serum malondialdehyde (MDA) and serum superoxide dismutase (SOD) were assessed at baseline and at the end of the study. A correlation analysis between previously reported serum asymmetric dimethylarginine (ADMA), serum MDA and serum SOD was performed.

Results: Febuxostat significantly decreased the serum MDA and significantly increased the serum SOD, while no significant results were observed in the placebo group. A highly positive correlation between the MDA levels and ADMA levels at baseline was noticed in both groups, while there was a highly negative correlation between the SOD levels and ADMA levels at baseline in both groups. A positive correlation between the change in ADMA levels and MDA levels from baseline was observed only in the drug group.

Conclusion: Febuxostat appears to have a direct ameliorating effect on oxidative stress in hemodialysis patients with endothelial dysfunction.

Keywords: Clinical trial; Endothelial dysfunction; Febuxostat; Hemodialysis; Oxidative stress.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nephrol Dial Transplant. 2000;15 Suppl 5:69-80 - PubMed
    1. Nephrol Dial Transplant. 2001 Sep;16(9):1742-5 - PubMed
    1. Circulation. 2001 Nov 27;104(22):2673-8 - PubMed
    1. J Am Coll Cardiol. 2002 Jan 16;39(2):257-65 - PubMed
    1. Clin Chem Lab Med. 2002 Feb;40(2):104-10 - PubMed

Publication types

LinkOut - more resources